Dollar remains weak ahead of Fed meeting; euro near highs
ATLANTA - Emory University Hospital has become the first hospital to adopt Microbot Medical Inc.’s (NASDAQ:MBOT) LIBERTY Endovascular Robotic System for patient care, according to a press release issued Wednesday. The small-cap medical robotics company, with a market capitalization of approximately $126 million, has seen its stock surge nearly 90% over the past year despite recent volatility.
The LIBERTY system, which received FDA clearance as a single-use, remotely operated robotic system for peripheral endovascular procedures, is designed to enable precise vascular navigation while reducing radiation exposure and physical strain for medical professionals. According to InvestingPro data, Microbot holds more cash than debt on its balance sheet, providing financial flexibility as it begins commercialization of this innovative system.
Microbot Medical has also announced a collaboration with Emory to establish an Endovascular Robotics Program in interventional radiology. The company began a limited market release of the system recently and plans a full market release at the Society of Interventional Radiology conference in April 2026. Despite the promising technology, InvestingPro analysis indicates the company is not yet profitable, with analysts forecasting continued losses this year.
"Introducing innovative technologies such as LIBERTY to our interventional radiology program underscores our priority to remain at the forefront of technological advancement," said J. David Prologo, MD, division director for Interventional Radiology at Emory University School of Medicine.
Emory clinicians plan to use the system for peripheral intervention procedures including liver tumor embolization, prostate artery embolization, and uterine fibroid embolization.
Harel Gadot, CEO, President and Chairman of Microbot Medical, described the adoption as "a major milestone for the entire surgical robotic space," noting that the company is "establishing a completely new medical robotic category with the adoption of the first FDA-cleared single-use robotic system."
Microbot Medical, based in Hingham, Massachusetts, focuses on developing robotic technology for endovascular procedures. The company commenced the limited market release of the LIBERTY system as part of its commercialization strategy.
In other recent news, Microbot Medical reported a net loss of $3.6 million for the third quarter of 2025, slightly exceeding the analyst’s projected loss of $3.4 million. The company ended September with $80.2 million in cash and investments, with negative cash flows from operating activities amounting to $3.8 million during the quarter. H.C. Wainwright has reiterated its Buy rating on Microbot Medical, maintaining a price target of $12.00. This follows the company’s announcement of a new logistics partnership to support the commercialization of its LIBERTY Endovascular Robotic System. The LIBERTY system, which received FDA 510(k) clearance in September, is now commercially available in the United States through a Limited Market Release. This system is the first FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot Medical is targeting high-procedure volume regions with established preliminary demand for the system. The company plans a broader launch in April 2026 at the Society of Interventional Radiology conference.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.